30930 Russell Ranch Road
About MannKind Corporation
MannKind Corporation (Nasdaq:MNKD ) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, the Technosphere® Insulin System, is currently in Phase 3 clinical trials in the U.S., Europe and Latin America to study its safety and efficacy in the treatment of diabetes.
MannKind is focusing on three areas:
- First, we are continuing to execute the Technosphere® Insulin clinical trial program.
- Second, we are moving our second potential product – a therapeutic cancer vaccine – through Phase 1 clinical trials.
- Third, we have begun clinical testing of the next product candidate for use with our Technosphere® platform technology.
Our values, like our work, combine the vision of our founder with the pragmatism of the laboratory. Teamwork, communication, trust and respect sum up the way we work and the way we treat our colleagues, while accountability, quality, and execution motivate the results we achieve. Finally, integrity and enthusiasm describe the spirit we bring to our jobs.
With around six hundred employees and three locations (in California, New Jersey, and Connecticut), we have grown significantly from our founding in 1991. We continue to be a tight-knit community where each of us has a critical role in our success. Committed to diversity, at MannKind we depend on a rich blend of ideas, backgrounds, and working styles in our quest to change the world for the better.
Last Updated: 04-01-2008
321 articles with MannKind Corporation
MannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI™ With New Drug Application Acceptance From the FDA
MannKind Corporation and United Therapeutics Corporation reached a major milestone with the announcement that the U.S. Food and Drug Administration accepted for priority review of the New Drug Application for Tyvaso DPI™ for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Both MannKind and United Therapeutics entered into a global and exclusive licensing and collaboration agreement to develop and commercialize Tyvaso DPI.
MannKind and Thirona Bio Join Forces to Evaluate Potential Inhaled Therapy for Fibrotic Lung Diseases
MannKind Corporation and Thirona Bio, Inc. announced that they have entered into a transaction that is intended to advance the development of a novel compound with potential for multiple indications.
This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.
MannKind Corporation announced today that its Chief Executive Officer, Michael Castagna, PharmD, will present at the Lytham Partners Summer 2021 Investor Conference on Monday, June 14, 2021 at 11:45 AM (ET).
MannKind Announces Data Presentation At 14th International Conference On Advanced Technologies & Treatments For Diabetes (ATTD 2021) To Be Held Virtually June 2-5
MannKind Corporation announced today that it will present a poster [Abstract #654 / Topic AS09 – New Insulin Delivery Systems: Inhaled, Transdermal, Implanted Devices] at the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2021) to be held virtually, June 2-5.
MannKind Corporation is revved up to announce an elevated partnership for the 2021 season with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes and will help raise awareness about diabetes and innovative management options.
MannKind Corporation reported financial results for the quarter ended March 31, 2021.
MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 at 4:15 pm.
MannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche
MannKind Corporation announced that on April 22, 2021 it and MidCap Financial Trust, as agent, entered into an amendment of the credit and security agreement dated August 6, 2019.
Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New Drug Application Submitted to the FDA
Following Afrezza®, Tyvaso DPI is the second compound formulated with Technosphere® technology to be reviewed by FDA
MannKind Announces Closing of Initial Purchasers’ Option to Purchase Additional Convertible Senior Notes - Mar 16, 2021
MannKind Corporation announced that on March 15, 2021 it issued an additional $30.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 pursuant to the exercise in full of the initial purchasers’ option in connection with MannKind’s previously-announced private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021 at 1:50 pm.
MannKind Corporation announced the pricing of $200.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
MannKind Corporation announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2026 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Conference Call to Begin Today at 9:00 AM ET 4Q 2020 Afrezza Net Revenue of $10.1 million; +30% vs. 4Q 2019 • Sequential Quarter Growth +38% vs. 3Q 2020 2020 Total Revenues of $65.1 million • 2020 Afrezza Net Revenue of $32.3 million; +28% vs. 2019 • 2020 Afrezza Gross Profit $17.2 million; 53% Gross Margin $67.2 million of Cash, Cash Equivalents and Restricted Cash at December 31, 2020 Acquired QrumPharma Inc. for $12.8 million in cash and stock
MannKind Corporation to Hold 2020 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2021
MannKind Corporation will release its 2020 fourth quarter and full year financial results and its management will host a conference call to discuss the financial results and corporate updates at 9:00 AM on Thursday, February 25, 2021.
MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the H.C. Wainwright Bioconnect 2021 Conference which will be available on demand starting on January 11, 2021 at 6:00 am (ET). Interested p
James S. Shannon Transitions to Chairman of the Board of Directors for MannKindKent Kresa, former Chairman, will continue to serve as a Director
MannKind Corporation announced that James S. Shannon, M.D., MRCP has been named the new Chairman of the Board of Directors effective December 9, 2020.
MannKind Expands Its Pipeline with the Acquisition of QrumPharma, Inc.Lead investigational product (inhaled clofazimine) designated by the FDA as an orphan drug and qualified infectious disease product
MannKind Corporation (N asdaq : MNKD) today announced that it has acquired QrumPharma, Inc., a privately held pharmaceutical company developing inhalation treatments for severe chronic and recurrent pulmonary infections, including Nontuberculous Mycobacterial (NTM) lung disease. “We have focused on building a stronger pipeline to treat unmet needs for orphan lung diseases, an area where we can leverage our experience and techn